June 27, 2014 9:54am EDT
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE:OPK), a multinational biopharmaceutical and
diagnostics company, today announced that the European Patent Office
granted OPKO a patent covering the company’s long-acting CTP-enhanced
human growth hormone product (Lagova), including composition of matter
and associated methods.
The new patent provides OPKO with additional intellectual property
protection covering Lagova in Europe, on top of other patents that were
previously granted in the U.S. by the U.S. Patent and Trademark Office.
OPKO recently announced strong positive results from a Phase 2 study of
Lagova in children with growth hormone deficiency. A Phase 3 of Lagova
in adults with growth hormone deficiency is ongoing.
About Lagova (hGH-CTP)
In June 2013, OPKO initiated a multi-center worldwide pivotal Phase 3
clinical trial in adults for its proprietary long-acting version of
Lagova. Lagova has been awarded orphan drug designation in the U.S. and
Europe for both adults and children with growth hormone deficiency.
ABOUT OPKO HEALTH
OPKO is a multinational biopharmaceutical and diagnostics company that
seeks to establish industry-leading positions in large, rapidly growing
markets by leveraging its discovery, development and commercialization
expertise and novel and proprietary technologies. For more information,
visit http://www.opko.com .
SAFE HARBOR STATEMENT
This press release contains "forward-looking statements," as that
term is defined under the Private Securities Litigation Reform Act of
1995 (PSLRA), which statements may be identified by words such as
"expects," "plans," "projects," "will," "may," "anticipates,"
"believes," "should," "intends," "estimates," and other words of similar
meaning, including statements regarding the potential benefits of
Lagova, whether additional patents will issue for Lagova, whether our
clinical trials for Lagova will be successful, whether we will
successfully develop or commercialize Lagova, as well as other
non-historical statements about our expectations, beliefs or intentions
regarding our business, technologies and products, financial condition,
strategies or prospects. Many factors could cause our actual activities
or results to differ materially from the activities and results
anticipated in forward-looking statements. These factors include those
described in our filings with the Securities and Exchange Commission,
and risks inherent in funding, developing and obtaining regulatory
approvals of new, commercially-viable and competitive products and
treatments. In addition, forward-looking statements may also be
adversely affected by general market factors, competitive product
development, product availability, federal and state regulations and
legislation, the regulatory process for new products and indications,
manufacturing issues that may arise, patent positions and litigation,
among other factors. The forward-looking statements contained in this
press release speak only as of the date the statements were made, and we
do not undertake any obligation to update forward-looking statements. We
intend that all forward-looking statements be subject to the safe-harbor
provisions of the PSLRA.
FTI Consulting
Investor Relations
Barbara Ryan, 212-850-5679
Managing
Director
or
Media
Relations
Kimberly Ha, 212-850-5612
Senior Director
Source: OPKO Health, Inc.
Released June 27, 2014
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page